Could Adamas Pharmaceuticals Inc (ADMS) Gain Strenght After Forming Descending Triangle?

July 17, 2017 - By Marie Mckinney

The stock of Adamas Pharmaceuticals Inc (ADMS) formed a descending triangle with $17.64 target or 4.00 % above today’s $16.96 share price. The 6 months triangle pattern indicates low risk for the $379.89 million company. If the $17.64 price target is reached, the company will be worth $15.20 million more.
The descending triangle is in our view more reliable than the ascending one. The descending triangle pattern has break even failure rate for up and down breakouts of 7% and 16%, respectively. The average rise and decline is 47% and 16%. The throwback or so called pullback rates are: 37% and 54%. The stocks meeting their targets is high for this type of breakout: 84% and 54% percent.

The stock decreased 0.18% or $0.03 during the last trading session, reaching $16.96. About 60,205 shares traded. Adamas Pharmaceuticals Inc (NASDAQ:ADMS) has declined 0.40% since July 17, 2016 and is downtrending. It has underperformed by 17.10% the S&P500.

Adamas Pharmaceuticals Inc (NASDAQ:ADMS) Ratings Coverage

Among 7 analysts covering Adamas Pharmaceuticals (NASDAQ:ADMS), 6 have Buy rating, 1 Sell and 0 Hold. Therefore 86% are positive. Adamas Pharmaceuticals had 13 analyst reports since August 7, 2015 according to SRatingsIntel. The firm earned “Market Outperform” rating on Friday, April 1 by JMP Securities. The rating was maintained by Mizuho with “Neutral” on Thursday, April 28. The firm earned “Outperform” rating on Thursday, December 24 by Credit Suisse. The firm earned “Buy” rating on Tuesday, September 22 by Aegis Capital. The rating was maintained by Mizuho on Tuesday, June 6 with “Buy”. On Friday, August 7 the stock rating was downgraded by Zacks to “Buy”. The company was initiated on Tuesday, January 19 by Mizuho. The firm has “Buy” rating by Noble Financial given on Friday, June 17. As per Friday, October 16, the company rating was downgraded by TheStreet. Cowen & Co initiated Adamas Pharmaceuticals Inc (NASDAQ:ADMS) rating on Tuesday, January 19. Cowen & Co has “Outperform” rating and $45 target.

More notable recent Adamas Pharmaceuticals Inc (NASDAQ:ADMS) news were published by: Globenewswire.com which released: “Adamas Reports Inducement Grant to New Chief Operating Officer” on May 05, 2017, also Globenewswire.com with their article: “Adamas Reports Inducement Grant to New Chief Financial Officer” published on July 10, 2017, Seekingalpha.com published: “Adamas Pharmaceuticals: Runup To Approval” on April 03, 2017. More interesting news about Adamas Pharmaceuticals Inc (NASDAQ:ADMS) were released by: Globenewswire.com and their article: “Adamas Announces New Employment Inducement Grant” published on March 10, 2017 as well as Globenewswire.com‘s news article titled: “Adamas to Present at Two Upcoming Investor Conferences” with publication date: June 01, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.